Lung Cancer

Most patients with lung cancer — including those receiving active therapy — produced neutralizing antibodies to COVID-19 after vaccination, according to study results.

Trastuzumab deruxtecan demonstrated strong antitumor activity among patients with previously treated HER2-mutated non-small cell lung cancer, according to results of a multicenter phase 2 trial presented during the virtual ESMO Congress.

The combination of nivolumab and ipilimumab maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results.

The FDA approved mobocertinib for treatment of certain patients with non-small cell lung cancer.

Alex A. Adjei, MD, PhD, FACP, will receive the 2021 ESMO Lifetime Achievement Award.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, according to study results.

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.

Older patients with late-stage non-small cell lung cancer appeared to benefit from immunotherapy, according to results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Patients with lung cancer reported high levels of anxiety and often experienced treatment delays during the COVID-19 pandemic, according to a single-center study conducted in Mexico.